Niagen Bioscience: How Its Shift To Telehealth Makes It A Strong Buy

Number Cruncher116 FollowersFollow5ShareSavePlay(10min)CommentsSummaryNiagen Bioscience is transitioning from supplements to a telehealth-driven longevity platform, targeting higher margins and valuations.I rate NAGE a Strong Buy at around $6-$8 per share, projecting 40% to 75% upside as the Niagen Plus injectable launches and the recurring revenue model matures.NAGE's IP moat, strategic patent acquisition, and direct-to-consumer telehealth strategy position it for premium HealthTech multiples versus supplement peers.Key risks include reliance on a sole NRC supplier and regulatory uncertainty; monitor Niagen Plus launch timing and customer adoption for re-rating catalysts. RamilF/iStock via Getty Images The market treats Niagen Bioscience (NAGE) as a traditional nutritional supplement company. However, it is undergoing a strategic transformation to become a leader in telehealth and longevity as a service. This sector offers exceptional profit margins andThis article was written byNumber Cruncher116 FollowersFollowIndependent Equity Researcher exploring global market opportunitiesAnalyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in NAGE over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.